Expert recommendations for the chronic disease management of rheumatic arthritis.
10.3760/cma.j.cn112138-20221219-00940
- Collective Name:Chronic Disease Management Group of Special Committee on Rheumatology and Immunology of Cross-Straits Medicine Exchange Association
- Publication Type:Journal Article
- MeSH:
Humans;
Rheumatic Fever;
Arthritis, Rheumatoid/drug therapy*;
Rheumatology;
Chronic Disease;
Disease Management;
Antirheumatic Agents/therapeutic use*
- From:
Chinese Journal of Internal Medicine
2023;62(11):1256-1265
- CountryChina
- Language:Chinese
-
Abstract:
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease that poses a major healthcare challenge. In China, approximately 5 million patients are reported to have RA. Notably, Chinese patients with RA often experience a prolonged disease course and increased disease activity, leading to a substantial disease burden. The Chronic Disease Management Group of the Special Committee on Rheumatology and Immunology of Cross-Straits Medicine Exchange Association has advocated for an all-encompassing, continuous, and proactive scientific management approach for RA. This initiative has culminated in the formulation of the "Expert Recommendations for the Chronic Disease Management of Rheumatoid Arthritis", a comprehensive guideline developed through extensive consultations and consideration of the unique characteristics of RA. We have outlined 16 expert recommendations, addressing 10 key aspects central to RA management. We aim to enhance treatment outcomes for patients, streamline the distribution of medical resources, and reduce treatment-related burden on society, families, and individuals affected by this condition.
